Jul 01, 2008 - Illumina, Inc. (NASDAQ:ILMN) announced that researchers participating in a new initiative funded by the Wellcome Trust selected Illumina's Infinium HD BeadChips to analyze 90,000 DNA samples. This new initiative aims to decipher the molecular basis of human disease and includes participation from leading research groups around the globe. Together, researchers at the Wellcome Trust Case Control Consortium 2 (WTCCC2) and 12 independent consortia will collect more than 120,000 DNA samples and analyze them for both single nucleotide polymorphisms (SNPs) and copy number variants (CNVs). This new series of genome-wide association studies are collectively the world's largest genetic research initiative conducted to date, and is expected to uncover genetic variants linked to many diseases such as multiple sclerosis, schizophrenia, and asthma. In addition to 90,000 samples collected from study participants, 6,000 control samples will be collected and analyzed using Illumina's Infinium HD Human1M-Duo BeadChip... Illumina's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
July
(29)
- Lorus Therapeutics : Allowance of New United State...
- Curis : Hsp90 Inhibitor CUDC-305 as Development Ca...
- AngioDynamics : Radiofrequency Ablation Yields Hig...
- ImmunoGen : Start of IMGN388 Clinical Testing
- Resolvyx Pharmaceuticals : First In-Vivo Data Sho...
- Illumina Infinium High-Density (HD) DNA Analysis P...
- Talecris Biotherapeutics : Orphan Drug Designation...
- FoldRx : Novel Therapeutic Approach for Treating C...
- Emergent BioSolutions and the University of Oxford...
- Nabi Biopharmaceuticals : Positive Interim Results...
- OSI Pharmaceuticals : Clinical Development Program...
- Threshold Pharmaceuticals : Interim Results From a...
- Genentech : Receipt of Proposal From Roche
- Alfacell : Novel Combination of Alfacell's ONCONAS...
- Luminex and ViroNovative : License Agreement for H...
- Schering-Plough and Merck & Co. : Withdrawal of L...
- RegeneRx : First Patent on TB4's Ability to Repair...
- BioNumerik Pharmaceuticals : Evidence of a Surviva...
- Advanced Life Sciences : Collaboration With UK Min...
- Genzyme Corporation and PTC Therapeutics : Collabo...
- Cyclacel : study of seliciclib synergy with Tarcev...
- Theravance : Clinical Results in the LAMA Respirat...
- Mpex : Phase 2 Clinical Trial of Aerosol MP-376 in...
- Aradigm : Phase 2 Data with Inhaled Liposomal Cipr...
- Novartis : strategic partnership with Lonza to acc...
- Znomics Launches Drug Discovery Program for Treatm...
- Icagen : Phase I Multiple Ascending Dose Clinical ...
- Micromet and Nycomed : Formal Preclinical Safety S...
- Cell Therapeutics : Complete Study Results Compari...
-
▼
July
(29)